Stephens raised the firm’s price target on Kymera Therapeutics (KYMR) to $100 from $95 and keeps an Overweight rating on the shares. Q4 results and the associated business update were in line with prior guidance and leave the 2026 investment narrative “largely unchanged,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk‑Reward
- Kymera Therapeutics price target raised to $120 from $110 at Citi
- Kymera Therapeutics Signals Strong Momentum In Earnings Call
- Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
- Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029